Interpace Diagnostics Group, Inc. (58) | Business Finance (18)

Browse by Subcategory

Recent Contracts

Security Agreement entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Asset Purchase Agreement by and among the Company and Diamir Biosciences Corp. dated March 16, 2021, . Upon the request of the SEC, the Company agrees to furnish copies of the... (Filed With SEC on May 11, 2021)
Joinder and Second Loan Modification Agreement, dated October 19, 2020, by and among the Company, Interpace Diagnostics Corporation, Interpace Diagnostics, LLC, Interpace Pharma... (Filed With SEC on October 23, 2020)
Consent to Assignment, dated July 19, 2019, by and among Meadows Landmark LLC, Cancer Genetics, Inc., and Interpace BioPharma, Inc (Filed With SEC on April 22, 2020)
Amended and Restated Investor Rights Agreement, dated as of January 15, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership (Filed With SEC on January 17, 2020)
Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (included as Exhibit A to the Securities Purchase and Exchange... (Filed With SEC on January 14, 2020)
Interpace Biosciences, Inc. Employee Stock Purchase Plan (Filed With SEC on November 14, 2019)
Equity Distribution Agreement, dated September 20, 2019, by and between Interpace Diagnostics Group, Inc. and Oppenheimer & Co. Inc (Filed With SEC on September 20, 2019)
Form of Underwriter Common Stock Purchase Warrant (Filed With SEC on January 29, 2019)
Underwriting Agreement, dated as of January 25, 2019, by and between Interpace Diagnostics Group, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on January 29, 2019)
Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)
First Loan Modification Agreement, dated March 18, 2019, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc. (n/k/a Interpace Biosciences, Inc.), Interpace... (Filed With SEC on October 19, 2020)
Loan and Security Agreement, dated November 13, 2018, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, and Interpace... (Filed With SEC on April 22, 2020)
Secured Creditor Asset Purchase Agreement, dated July 15, 2019, by and among Interpace BioPharma, Inc., Cancer Genetics, Inc., Interpace Diagnostics Group, Inc. and Partners for... (Filed With SEC on July 19, 2019)
Investor Rights Agreement, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Ampersand 2018 Limited Partnership (Filed With SEC on July 19, 2019)
Securities Purchase Agreement, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Ampersand 2018 Limited Partnership (Filed With SEC on July 19, 2019)
Subordinated Seller Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc (Filed With SEC on July 19, 2019)